Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation

BMC Musculoskeletal Disorders

Michael T Nurmohamed²  Yvo M Smulders²  Irene E Van der Horst-Bruinsma¹  Mike J Peters²  Alper M Van Sijl²  Inge A Van den Oever¹  Sjoerd C Heslinga² 

[1] Department of Rheumatology, VU University Medical Centre, Amsterdam, Netherlands;Department of Internal Medicine, VU University Medical Centre, Amsterdam, Netherlands

关键词: Treatment;    Smoking;    Hypertension;    Risk factors;    Ankylosing Spondylitis;   

Others  :  1173914
DOI  :  10.1186/s12891-015-0532-3

 received in 2014-09-18, accepted in 2015-03-18,  发布年份 2015

【 摘 要 】

Background

Ankylosing spondylitis (AS) is an inflammatory disease with documented elevated cardiovascular (CV) risk due to systemic inflammation and a higher prevalence of CV risk factors. CV risk management (CV-RM) could be an effective method to reduce CV mortality and morbidity in AS patients. We assessed CV risk and evaluated guideline adherence according to the Dutch CV-RM guideline.

Methods

This study was conducted with a cohort of consecutive AS patients eligible for treatment with a tumor necrosis factor (TNF) -α inhibitor. Data from the Dutch National Institute for Public Health and Environment was used to compare the prevalence of CV risk factors in AS patients with the Dutch background population.

Results

In total, 254 consecutive AS patients were included. The prevalences of hypertension (41% vs 31%) and smoking (43% vs 27%) were substantially higher in AS patients as compared to the general Dutch background population. Of 138 AS patients older than 40 years the 10-years CV risk could be calculated. Fifty-one of these 138 patients (37%) had an indication for CV risk treatment. CV risk treatment was initiated in 42 of the 51 (82%), however, in only 12 of the 51 (24%) patients treatment targets for either hypertension or hypercholesterolemia were reached.

Conclusion

The increased rates of hypertension and smoking illustrate the importance of CV-RM in AS patients. Although the majority of all AS patients eligible for CV-RM received CV risk medication, CV-RM remains a challenge for treating physicians, as treatment targets were not achieved in three-quarter of the eligible patients.

【 授权许可】

   
2015 Heslinga et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT: Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004, 34:585-92.
• [2]Bakland G, Gran JT, Nossent JC: Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011, 70:1921-5.
• [3]Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-38.
• [4]Mathieu S, Gossec L, Dougados M, Soubrier M: Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken ) 2011, 63:557-63.
• [5]Bremander A, Petersson IF, Bergman S, Englund M: Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken ) 2011, 63:550-6.
• [6]Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV: Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33:2167-72.
• [7]Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al.: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl 2):S49-73.
• [8]Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren M, et al.: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-701.
• [9]Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al.: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-31.
• [10]Papagoras C, Voulgari PV, Drosos AA: Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013, 31:612-20.
• [11]Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, et al.: The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009, 88:358-65.
• [12]Peters MJ, van Eijk IC, Smulders YM, Serne E, Dijkmans BA, van der Horst-Bruinsma IE, et al.: Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010, 37:161-6.
• [13]van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-8.
• [14]Nederlandse Vereniging voor Reumatologie (NVR): Richtlijn "Verantwoord gebruik van biologicals", http://www.nvr.nl/wp-content/uploads/2014/11/NVR-Medicijnen-richtlijn-verantwoord-gebruik-van-biologicals-januari-2011.pdf
• [15]TNS-NIPO, www.tns-nipo.com/pages/persvannipo/pdf/stivoro_aantalrokers08_0109.pdf. Accessed March 2014.;.
• [16]RIVM, http://www.nationaalkompas.nl/gezondheidsdeterminanten. Accessed March 2014.;.
• [17]Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al.: Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-9.
• [18]Multidisciplinary guideline on cardiovascular risk management. https://www.nhg.org/sites/default/files/content/nhg_org/uploads/cardiovasculair-risicomanagement.pdf.
• [19]Sundstrom B, Johansson G, Johansson I, Wallberg-Jonsson S: Modifiable cardiovascular risk factors in patients with ankylosing spondylitis. Clin Rheumatol 2014, 33:111-7.